


Content from /en/blog/ibd-oversigt/

Inflammatory bowel disease (IBD): overview of ulcerative colitis and Crohn's disease



Inflammatory bowel disease (IBD) is the umbrella term for two autoimmune diseases causing persistent or relapsing inflammation of the digestive tract: **ulcerative colitis (UC)** and **Crohn's disease (CD)**. In Denmark approximately **65,000 people** live with IBD, one of the highest rates worldwide [1]. Onset is typically aged 15-35 but can occur at any age.

The two forms - at a glance

Feature	<u>Ulcerative colitis (UC)</u>	Crohn's disease (CD)
Location	Colon only, from rectum upwards	Entire GI tract (mouth → anus)

Feature	<u>Ulcerative colitis (UC)</u>	Crohn's disease (CD)
Inflammation depth	Mucosa only	Whole bowel wall (transmural)
Distribution	Continuous	Patchy ("skip lesions")
Classic symptoms	Bloody diarrhoea, tenesmus	Abdominal pain, weight loss, fistulas
Complications	Toxic megacolon, <u>colorectal cancer</u>	Strictures, fistulas, abscesses
Smoking	Protective (paradoxical)	Worsens course
Surgery	Curative by colectomy	Not curative

→ For the full comparison: [Crohn's disease vs. ulcerative colitis](#).

Symptoms

Bowel symptoms:

- Chronic or bloody diarrhoea (>4 weeks)
- Abdominal pain, often cramping
- Tenesmus (painful urge to defecate)
- Rectal bleeding
- Black stool (rare, upper Crohn's)
- Weight loss, anorexia

Extraintestinal manifestations (up to 40 %):

- Joints (arthritis, sacroiliitis)
- Skin (erythema nodosum, pyoderma gangrenosum)
- Eyes (uveitis, episcleritis)

- Liver (primary sclerosing cholangitis, especially UC)
- Osteoporosis from corticosteroids

Alarm symptoms (acute):

- Severe rectal bleeding
 - Fever $>38.5^{\circ}\text{C}$
 - Signs of toxic megacolon (rare, life-threatening)
 - Suspected perforation
-

Diagnosis

1. History and clinical examination.

2. **Blood tests:** haemoglobin (anaemia), CRP, white cells, albumin, ferritin, B12, folate.

3. **Faecal calprotectin** - very sensitive marker of intestinal inflammation; used to distinguish IBD from IBS.

4. **Stool studies** - exclude infectious colitis (*C. difficile*, *Salmonella*, *Shigella*, *Campylobacter*).

5. **Colonoscopy with multiple biopsies** - gold standard. Assesses extent, severity, morphology.

6. **Gastroscopy** when upper Crohn involvement is suspected.

7. **MR enterography** or **capsule endoscopy** for small-bowel assessment (especially Crohn's).

8. **CT abdomen** in acute complications.

Treatment - stepwise

Inducing remission:

- **Mild-moderate UC:** 5-ASA (mesalazine) topical and/or oral
- **Moderate-severe:** systemic corticosteroids (prednisolone)
- **Severe acute:** IV corticosteroids, possibly ciclosporin or infliximab

Maintaining remission:

- **UC:** lifelong 5-ASA
- **CD:** thiopurines (azathioprine) or methotrexate
- **Biologics** for severe or refractory disease: anti-TNF (infliximab, adalimumab), vedolizumab, ustekinumab, JAK inhibitors (tofacitinib, upadacitinib)
- **"Treat-to-target" strategy** aiming at histological healing [2]

Surgery:

- **UC:** total colectomy is curative - considered for medical failure or dysplasia
- **CD:** resection of complications (strictures, fistulas) - not curative; needed in 50-70 % over a lifetime [3]

Monitoring and prevention

- **Colorectal cancer screening:** colonoscopy 8-10 years after disease onset, then every 1-5 years by risk.
- **Vaccinations:** influenza, pneumococcus, HPV, hepatitis B before biologic therapy.
- **Bone density** with chronic steroid use.
- **Psychosocial support** and dietitian.

Treatment at Kirurgen.dk

We offer colonoscopy for primary IBD work-up and surveillance, gastroscopy for upper symptoms, and collaborate with gastroenterology and surgical departments for complex patients. See also: Ulcerative colitis, Crohn's disease, Crohn vs. ulcerative colitis, Microscopic colitis.

References

1. Lophaven SN, Lynge E, Burisch J. *The incidence of inflammatory bowel disease in Denmark 1980-2013*. Aliment Pharmacol Ther 2017;45(7):961-72.

2. Turner D, Ricciuto A, Lewis A, et al. *STRIDE-II: an update on the Selecting Therapeutic Targets in IBD (STRIDE) initiative*. Gastroenterology 2021;160(5):1570-83.
3. Frolkis AD, Dykeman J, Negrón ME, et al. *Risk of surgery for inflammatory bowel diseases has decreased over time*. Gastroenterology 2013;145(5):996-1006.